Phase 2 Pancreatitis Trial, Recruiting NCT05160506 Sponsor: Beth Israel Deaconess Medical Center Condition: Pancreatitis
Back to Pancreatitis

Phase 2 Pancreatitis Trial, Recruiting

NCT05160506
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older.
  • People who have been diagnosed with acute pancreatitis, confirmed by symptoms and a blood test showing a specific enzyme (lipase) at least 3 times higher than the normal upper limit.
  • People who have been admitted, or are planned to be admitted, to an intensive care unit (ICU).
  • People with a disease severity score (called a SOFA score) of 3 or higher, or at least 3 points above their known starting level (confirm with trial site).

Who may not be able to join:

  • People who have a known diagnosis of autoimmune pancreatitis (a specific type of pancreatitis caused by the immune system).
  • People who already have a medical reason to take corticosteroid medication (a type of anti-inflammatory drug) at a dose higher than 5mg of oral prednisone per day, or an equivalent amount of a similar medication.
  • People for whom taking corticosteroids would be medically unsafe or not recommended for any reason.
  • People who are currently incarcerated (prisoners).
  • People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michael Donnino, MD, Beth Israel Deaconess Medical Center

Phone: 6177542295

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
6 March 2022
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Severity of Illness Measure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov